Drugs & Aging

, Volume 3, Issue 5, pp 460–478 | Cite as

Tiapride

A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Geriatric Agitation
  • John W. Steele
  • Diana Faulds
  • Eugene M. Sorkin
Drug Evaluation

Abstract

Synopsis

Tiapride is a substituted benzamide derivative with selective dopamine D2-receptor antagonist properties which appears to have preferential affinity for extrastriatal dopamine receptors. Animal and clinical studies show that tiapride has anxiolytic properties but the mechanism of action is uncertain. Results from limited studies indicate that the clinical efficacy of tiapride in the treatment of agitation, aggressiveness, anxiety and sleep disorders in the elderly appears superior to that of placebo, chlorpromazine, lorazepam and meprobamate. Tiapride also exerts a beneficial effect on vigilance and alertness in elderly patients and causes less sedation than chlorpromazine. Tiapride is well tolerated at the dosages recommended for elderly patients.

Further well designed comparative studies with newer drugs are needed to determine the relative place of tiapride in the treatment of geriatric agitation, and such studies should also address the quality-of life benefits for the patient. Additional clinical experience to determine the efficacy of tiapride in elderly patients with more than one disease condition, receiving concomitant medications, and/or with renal impairment is also required. However, despite these current limitations, tiapride may have potentially important applications in this difficult area of clinical medicine.

Pharmacodynamic Properties

Tiapride, an atypical neuroleptic drug, is a selective dopamine D2-receptor antagonist, and is particularly active at receptors which have been sensitised to dopamine. In vivo studies show that it binds preferentially to dopamine receptors in extrastriatal rat brain tissue, particularly in the hippocampus. Affinity for D1-receptors is very weak and the exact nature and clinical significance of the reported affinity for dopamine receptor subtypes remains to be determined. Tiapride has not been shown to have clinically significant effects on other receptors, although the mechanism of its anxiolytic activity remains uncertain.

In stress model tests in rodents, tiapride ⩾0.5 mg/kg displayed anxiolytic properties equipotent with diazepam 0.125 mg/kg and triazolam 0.1 mg/kg, and intraperitoneal tiapride 10 mg/kg twice daily did not cause withdrawal effects, unlike intraperitoneal diazepam at the same dosage. There was no marked sedative effect in rats receiving tiapride 40 mg/kg but the catalepsy-inducing effects of haloperidol or chlorpromazine were potentiated. High doses also potentiated the muscle relaxant properties of diazepam in mice.

In common with other dopaminergic antagonists, tiapride caused an increase in prolactin; however, the effects of prolonged elevation of prolactin in the elderly are unknown. Tiapride also has a beneficial effect on vigilance and alertness in elderly patients, which are useful adjunctive properties in the therapy of anxiety, agitation or aggressiveness.

Pharmacokinetic Properties

Tiapride is about 75% absorbed following oral or intramuscular administration in healthy volunteers. Distribution is rapid and peak plasma concentrations are reached in about 0.5 to 1.0h after oral or intramuscular administration. There is no evidence of protein binding or clinically significant accumulation of tiapride. The elimination half-life of tiapride in healthy young volunteers and patients is between 3 and 5 hours. Most of the dose is eliminated unchanged in the urine, with a small percentage as de-ethylated and N-oxide metabolites. Dosage reduction is required in patients with renal impairment.

Therapeutic Use in Geriatric Agitation

Tiapride 200 to 300 mg/day is recommended as an anxiolytic drug in elderly patients, with onset of action from a few to 14 days. Comparative studies have shown that tiapride at dosages of 75 to 150 mg/day, 150 mg/day, or 75 to 300 mg/day orally, and 400 mg/day intramuscularly, is significantly better in controlling senile agitation, behavioural problems and related conditions than placebo, lorazepam (3 mg/day), chlorpromazine (18.75 to 75 mg/day) or meprobamate (800 mg/day intramuscularly) respectively.

Although a substantial number of noncomparative studies had design and assessment deficiencies, they indicate that tiapride 50 to 1200 mg/day in elderly patients has some effect in relieving agitation, aggressiveness and anxiety. In addition, there is evidence to suggest that tiapride also improves alertness and vigilance in the elderly.

Tolerability

Tiapride was well tolerated in elderly patients in noncomparative and comparative clinical trials over periods ranging from 3 days to several years. The reported adverse effects most likely to occur in the elderly are drowsiness, agitation, dyskinesia, digestive problems, dizziness and weakness. Only extrapyramidal reactions (4%) and drowsiness (6.7%) occur more frequently in the elderly than in the general population (2.5 and 5%, respectively). At therapeutic dosages, tiapride caused less sedation than chlorpromazine. Other adverse events are regarded as mild, and reversible on tiapride withdrawal. In a double-blind comparative study in 134 elderly patients after cerebrovascular accidents, the effect of tiapride 75 to 150 mg/day on daily activities and tolerability was not significantly different from placebo.

Dosage and Administration

The recommended dosage of tiapride in elderly patients is 200 to 300 mg/day in divided doses for up to 2 months. Therapy may be continued for longer periods following medical reassessment. Patients with renal impairment may require dosage reduction.

Keywords

Dopamine Receptor Metoclopramide Chlorpromazine Tardive Dyskinesia Sulpiride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albertini F. Mémorisation et céphalées. Semaine des Hôpitaux 54: 1257–1259, 1978PubMedGoogle Scholar
  2. Ames D, Tuckwell V. Psychopharmacology in the 1990s. What does the future hold for the aged patient? Drugs and Aging 1: 339–344, 1991PubMedCrossRefGoogle Scholar
  3. Andersen PH, Nielsen EB. Novel approaches to development of antipsychotics. Drug News and Perspectives 4: 150–157, 1991Google Scholar
  4. Anonymous. Tiapride Prescribing Information, France, 1993Google Scholar
  5. Anonymous. Tiapride Product Monograph. Laboratoires Delagrange Synthélabo, 1981Google Scholar
  6. Arima T, Samura N, Nomura Y, Segawa T. Comparison of effects of tiapride and sulpiride on D-1, D-2, D-3 and D-4 subtypes of dopamine receptors in rat striatal and bovine caudate nucleus membranes. Japanese Journal of Pharmacology 41: 419–423, 1986PubMedCrossRefGoogle Scholar
  7. Attali G, Bergeot R, Fournier N, Viau G, Leroux R. Quantification des handicaps des personnes âgées. Revue de Médecine de Tours 14: 1521–1524, 1980Google Scholar
  8. Attali G, Leroux R. Traitement de l’information dans un service de gériatrie. Revue de Gériatrie 7: 5–7, 1982Google Scholar
  9. Barry JM, Costall B, Kelly ME, Naylor RJ. Withdrawal syndrome following subchronic treatment with anxiolytic agents. Pharmacology Biochemistry and Behavior 27: 239–245, 1987CrossRefGoogle Scholar
  10. Billig N, Cohen-Mansfield J, Lipson S. Pharmacological treatment of agitation in a nursing home. Journal of the American Geriatrics Society 39: 1002–1005, 1991PubMedGoogle Scholar
  11. Bischoff S, Bittiger H, Delini-Stula A, Ortmann R. Septo-hippocampal system: target for substituted benzamides? European Journal of Pharmacology 79: 225–232, 1982PubMedCrossRefGoogle Scholar
  12. Bondarenko NA, Gorantcheva J, Tyutyulkova N, Nokolova M, Valdman AV. Effects of some benzamide derivatives on stress-induced behavior and striatum dopamine receptors. Methods and Findings in Experimental and Clinical Pharmacology 10: 629–633, 1988PubMedGoogle Scholar
  13. Bressolle F, Brès J, Mourad G. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function. Clinical Pharmacokinetics 17: 367–373, 1989PubMedCrossRefGoogle Scholar
  14. Bruhwyler J, Chleide E, Liégeois J-F, Delarge J, Mercier M. Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test. Pharmacology Biochemistry and Behavior 36: 57–61, 1990CrossRefGoogle Scholar
  15. Bruhwyler J, Chleide E, Liegeois JF, Delarge J, Mercier M. Effects of specific dopaminergic agonists and antagonists in the open-field test. Pharmacology Biochemistry and Behavior 39: 367–371, 1991CrossRefGoogle Scholar
  16. Chevaillier G, Dessertenne P, Pelletier P. Nouvelle possibilité thérapeutique en pratique gériatrique. Semaine des Hôpitaux 54: 878–880, 1978PubMedGoogle Scholar
  17. Cheymol G, Mouillé P. Étude des effets anti-arythmisants de dérivés du métoclopramide. Archives Internationales de Pharmacodynamic et de Therapie 215: 150–159, 1975Google Scholar
  18. Chivers JK, Gommeren W, Jenner P, Leysen J, Marsden CD, et al. Comparison of in vivo and in vitro actions of tiapride on rodents. Abstract. British Journal of Pharmacology 79(Suppl.): 398P, 1983Google Scholar
  19. Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors. Journal of Pharmacy and Pharmacology 40: 415–421, 1988PubMedCrossRefGoogle Scholar
  20. Cohen-Mansfield J. Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society 34: 722–727, 1986PubMedGoogle Scholar
  21. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. Journal of the American Geriatrics Society 34: 711–721, 1986PubMedGoogle Scholar
  22. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. Journal of Gerontology 44: M77–84, 1989PubMedGoogle Scholar
  23. Costall B, Kelly ME, Naylor RJ. The production of asymmetry and circling behaviour following unilateral, intrastriatal administration of neuroleptic agents: a comparison of abilities to antagonise striatal function. European Journal of Pharmacology 96: 79–86, 1983PubMedCrossRefGoogle Scholar
  24. Costall B, Kelly ME, Naylor RJ. Unilateral striatal dopamine denervation: reduced motor inhibitory effects of dopamine antagonists revealed in models of asymmetric and circling behaviour. Naunyn-Schmiedeberg’s Archives of Pharmacology 326: 29–35, 1984PubMedCrossRefGoogle Scholar
  25. Costall B, Kelly ME, Naylor RJ. The anxiolytic and anxiogenic actions of ethanol in a mouse model. Journal of Pharmacy and Pharmacology 40: 197–202, 1987CrossRefGoogle Scholar
  26. Costall B, Naylor RJ. Experimental studies of dopamine function in movement disorders. In Neurotransmitter systems and their clinical disorders, Academic Press, London, 1977Google Scholar
  27. Costall B, Naylor RJ. Assessment of the test procedures used to analyse neuroleptic action. Review of Pure and Applied Pharmacological Sciences 1: 3, 1980Google Scholar
  28. Costall B, Naylor RJ, Nohria V. Use of the mouse circling model to demonstrate enhanced striatal actions for oxiperomide and tiapride following denervation. British Journal of Pharmacology 66: 121P, 1979Google Scholar
  29. Costall B, Naylor RJ, Owen RT. Investigations into the nature of the peri-oral movements induced by 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin. European Journal of Pharmacology 45: 357–367, 1977PubMedCrossRefGoogle Scholar
  30. Costall B, Naylor RJ, Owen RT. Gabaminergic and serotonergic modulation of the antidyskinetic effects of tiapride and oxiperomide in the model using 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin. European Journal of Pharmacology 49: 407–413, 1978PubMedCrossRefGoogle Scholar
  31. Coudreuse JF. Utilisation du tiapride dans une maison de retraite médicalisée. Semaine des Hôpitaux 60: 2855–2859, 1984Google Scholar
  32. Csernansky JG, Csernansky CA, Hollister LE. 3[H]-Sulpiride labels mesolimbic non-dopaminergic sites that bind antidepressant drugs. Experientia 41: 1419–1421, 1985PubMedCrossRefGoogle Scholar
  33. Dechelotte R. Le tiapridal en gériatrie. Semaine des Hôpitaux 53: 475–478, 1977Google Scholar
  34. Deligné P, Bunodière M. Neuroplégiques et neuroleptiques antipsychotiques. VIII - Les benzamides (lère partie). Annales de l’Anesthésiologie Française 1: 97–110, 1980aGoogle Scholar
  35. Elliott PNC, Jenner P, Huizing G, Marsden CD, Miller R. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology 16: 333–342, 1977PubMedCrossRefGoogle Scholar
  36. Fontaine J, Reuse J. Pharmacological analysis of the effects of substituted benzamides on the isolated guinea-pig ileum. Study of metoclopramide, sulpiride, bromopride, tiapride, and sultopride. Archives Internationales de Pharmacodynamic et de Therapie 235: 51–61, 1978Google Scholar
  37. Fontaine J, Reuse J. The effects of substituted benzamides on frog rectus abdominis. European Journal of Pharmacology 68: 55–60, 1980PubMedCrossRefGoogle Scholar
  38. Fortune DH, Costall B, Naylor RJ. Tiapride binds to mouse striatal tissue pre-exposed to dopamine stimulation. Journal of Pharmacy and Pharmacology 32: 514–517, 1980.PubMedCrossRefGoogle Scholar
  39. François F. Troubles neurologiques et psychiatriques de la senescence. Essai de traitement par le tiapride. Medicine Interne 10: 371–374, 1975Google Scholar
  40. Ged E, Perrotin D, Lanotte R, Ginies G. Traitement du Delirium tremens par le tiapride et syndrome malin des neuroleptiques. Presse Médicale 15: 1047–1048, 1986Google Scholar
  41. Gennari C, Nami R, Pizzuti M, D’Ascenzo G, Bianchini C. Effets du tiapride sur le taux plasmatique de beta-endorphine, prolactine et dopamine chez des patients souffrant d’algies cancéreuses. Semaine des Hôpitaux 57: 795–800, 1981PubMedGoogle Scholar
  42. Grossberg GT. The pitfalls of metaanalysis. Journal of the American Geriatrics Society 38: 607, 1990PubMedGoogle Scholar
  43. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran-Johnson TK, et al. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacology Bulletin 28: 87–92, 1992PubMedGoogle Scholar
  44. Hermesh H, Huberman M, Radvan H, Kott E. Recurrent neuroleptic malignant syndrome due to tiapride and haloperidol: the possible role of D-2 dopamine receptors. Single case study. Journal of Nervous and Mental Disease 172: 692–695, 1984PubMedCrossRefGoogle Scholar
  45. Honma A, Hasegawa K. Experience with the use of tiapride in geriatric mental disorders, combined with a study of serum levels. [Translated into English from Japanese.] Shinyaku to Rinsho 34: 17–26, 1985Google Scholar
  46. Horton RW, Lowther S, Chivers J, Jenner P, Marsden CD, et al. The interaction of substituted benzamides with brain benzodiazepine binding sites in vitro. British Journal of Pharmacology 94: 1234–1240, 1988PubMedCrossRefGoogle Scholar
  47. Indo T, Tokuma Y, Noguchi M. Pharmacokinetics of a single dose of tiapride in geriatric patients. [Translated into English from Japanese.] Kiso to Rinsho 18: 311–318, 1984Google Scholar
  48. Ishii S, Taguchi K, Suemaru K, Ishino H, Suzuki K. Clinical effects of tiapride in patients with senile organic psychosis. [Translated into English from Japanese.] Yakuri to Chiryo 12: 281–292, 1984Google Scholar
  49. Ishino H, Imaoka N, Mitsunobu K, Endoh H, Sugano H, et al. Clinical experience of tiapride fine granule in patients with senile or presenile organic psychosis. [Translated into English from Japanese.] Yakuri to Chiryo 12: 271–279, 1984Google Scholar
  50. Jenner P, Theodorou A, Marsden CD. Specific receptors for substituted benzamide drugs in brain. In Rotrosen & Stanley (Eds) The benzamides: pharmacology, neurobiology, and clinical aspects, advances in biochemical psychopharmacology, Vol. 35, pp. 109–141, Raven Press, New York, 1982Google Scholar
  51. Jones B. 5-HT3 Receptor antagonists in anxiety and schizophrenia. Drug News and Perspectives 3: 106–111, 1990Google Scholar
  52. Kamizono A, Inotsume N, Miyamoto K, Ueda K, Miyakawa T, et al. Determination of sultopride and tiapride in serum by gas chromatography using a surface ionisation detector. Journal of Chromatography 567: 113–120, 1991PubMedCrossRefGoogle Scholar
  53. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 277: 93–96, 1979PubMedCrossRefGoogle Scholar
  54. Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica 82(Suppl. 358): 27–36, 1990CrossRefGoogle Scholar
  55. Lacroix G. Agitation des déments séniles hospitalisés. Traitement par le tiapride. Semaine des Hôpitaux 66: 1379–1381, 1990Google Scholar
  56. L’Hermite M, MacLeod RM, Robyn C. Effects of two substituted benzamides, tiapride and sultopride, on gonadotrophins and prolactin. Acta Endocrinologica 89: 29–37, 1978PubMedGoogle Scholar
  57. L’Hermite M, Michaux-Duchêne A, Robyn C. Tiapride-induced chronic hyperprolactinaemia: interference with the human menstrual cycle. Acta Endocrinologica 92: 214–227, 1979PubMedGoogle Scholar
  58. Lin CW, Wilk S. A comparison of the effect of substituted benzamides in radioreceptor binding assays with their effects on brain dopaminergic systems in vivo. In Rotrosen & Stanley (Eds) The benzamides: pharmacology, neurobiology, and clinical aspects, advances in biochemical psychopharmacology, Vol. 35, pp. 51–60, Raven Press, New York, 1982.Google Scholar
  59. Lindesay J, Briggs K, Murphy E. The Guy’s/Age Concern Survey. Prevalence rates of cognitive impairment, depression and anxiety in an urban elderly community. British Journal of Psychiatry 155: 317–329, 1989PubMedGoogle Scholar
  60. Meltzer HY, So R, Fang VS. Effect of benzamide drugs on prolactin secretion: relation to the dopamine receptor. In Rotrosen & Stanley (Eds) The benzamides: pharmacology, neurobiology, and clinical aspects, advances in biochemical psychopharmacology, Vol. 35, pp. 61–82, Raven Press, New York, 1982Google Scholar
  61. Micheli F, Casas Parera I, Cabo H, Schteinschnaider A, Giannaula R. Tiapride-induced erythema multiforme. Clinical Neuropharmacology 11: 556–558, 1988PubMedCrossRefGoogle Scholar
  62. Mikawa I, Saito Y, Yokoyama O. Pharmacokinetics of tiapride in blood and its excretion in urine of patients with disturbed renal function. [Translated into English from Japanese.] Kiso to Rinsho 18: 553–558, 1984Google Scholar
  63. Miletto G, Julou M. Le tiapride en neurologie et eh psychiatrie chez la personne âgée. Semaine des Hôpitaux 57: 1833–1836, 1981PubMedGoogle Scholar
  64. Mills A. Dopamine: from Cinderella to Holy Grail. Trends in Pharmacological Sciences 13, 399–400, 1992PubMedCrossRefGoogle Scholar
  65. Morgenstern R, Fink H. Sulpiride blocks postsynaptic dopamine receptors in the nucleus accumbens. Journal of Neural Transmission 61: 151–160, 1985PubMedCrossRefGoogle Scholar
  66. Mouillé P, Cheymol G. Effets cardiovasculaire et hémodynamiques de dérivés du métoclopramide. Archives Internationales de Pharmacodynamic et de Therapie 215: 139–149, 1975Google Scholar
  67. Nandakumaran M, Challier J-C, Rey E, Richard M-O, Olive G. In vitro transfer of six benzamides in the human placenta. Developmental Pharmacology and Therapeutics 7(Suppl. 1): 60–66, 1984PubMedGoogle Scholar
  68. Nohria V, Costall B, Naylor RJ. Dopamine antagonist properties of atypical neuroleptics may be revealed following mesolimbic denervation. International Pharmacopsychiatry 16: 21–29, 1981PubMedGoogle Scholar
  69. Norman T, Chiu E, James RH, Gregory MS. Single oral dose pharmacokinetics of tiapride in patients with Huntington’s disease. European Journal of Clinical Pharmacology 32: 583–586, 1987PubMedCrossRefGoogle Scholar
  70. Norman TR, James RH, Gregory MS. Determination of tiapride in plasma by high-performance liquid chromatography. Journal of Chromatography 375: 197–201, 1986CrossRefGoogle Scholar
  71. Nowak TV, Schulze-Delrieu K. The substituted benzamides in gastroenterology. In Rotrosen & Stanley (Eds) The benzamides: pharmacology, neurobiology, and clinical aspects, advances in biochemical psychopharmacology, Vol. 35, pp. 195–203, Raven Press, New York, 1982Google Scholar
  72. Ohtomo E, Urasawa K, Tohgi H, Hirai S, Terashi A, et al. Clinical usefulness of tiapride in treatment of psychiatric symptoms caused by cerebral infarction. A multi-center double-blind study in comparison with inactive placebo. [Translated into English from Japanese.] Rinsho Igaku 5, 1243–1271, 1989Google Scholar
  73. Perez Y, De Lacharriere O, Valcke JC, Benit C, Moreau L. Syndrome malin des neuroleptiques dû au tiapride et complications neurologiques. Presse Médicale 18: 585, 1989Google Scholar
  74. Peselow ED, Stanley M. Clinical trials of benzamides in psychiatry. In Rotrosen & Stanley (Eds) The benzamides: pharmacology, neurobiology, and clinical aspects, advances in biochemical psychopharmacology, Vol. 35, pp. 163–194, Raven Press, New York, 1982Google Scholar
  75. Peyramond A. Étude comparative croisée de Taction du tiapride et du méprobamate sur les états d’agitation. Semaine des Hôpitaux 54: 542–545, 1978PubMedGoogle Scholar
  76. Puech AJ, Lecrubier Y, Simon P. Pharmacological classification of benzamides. Acta Psychiatrica Scandinavica 311(Suppl.): 139–145, 1984PubMedCrossRefGoogle Scholar
  77. Puech AJ, Simon P, Boissier JR. Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. European Journal of Pharmacology 50: 291–300, 1978PubMedCrossRefGoogle Scholar
  78. Rey E, d’Athis Ph, Richard MO, de Lauture D, Olive G. Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 62–67, 1982aGoogle Scholar
  79. Rey E, d’Athis Ph, Richard MO, de Lauture D, Olive G. Influence de repas sur la biodisponsibilité d’une forme orale du tiapride. Therapie 37: 651–656, 1982bPubMedGoogle Scholar
  80. Rondanelli R, Regazzi MB, Cristiani D, Ciardelli L. Cinetica della tiapride e biodisponibilità relativa di due preparati per os. Rivista Italiana di Biologia e Medicina 3: 237–244, 1983Google Scholar
  81. Roos RAC, de Haas EJM, Buruma OJS, de Wolff FA. Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington’s disease. European Journal of Clinical Pharmacology 31: 191–194, 1986PubMedCrossRefGoogle Scholar
  82. Rosen J, Mulsant BH, Wright BA. Agitation in severely demented patients. Annals of Clinical Psychiatry 4: 207–215, 1992CrossRefGoogle Scholar
  83. Roufogalis BD, Thornton M, Wade DN. Specificity of the dopamine sensitive adenylate cyclase for antipsychotic antagonists. Life Sciences 19: 927–934, 1976PubMedCrossRefGoogle Scholar
  84. Rouquet JP, Bezaury JP. Traitment de l’agitation dans les états démentiels. Étude comparative, en ouvert, de Taction du tiapride et du lorazepam. Semaine des Hôpitaux 60: 3086–3088, 1984Google Scholar
  85. Rovner BW, Rabins PV. Mental illness among nursing home patients. Hospital and Community Psychiatry 36: 119–128, 1985PubMedGoogle Scholar
  86. Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF. Prevalence of mental illness in a community nursing home. American Journal of Psychiatry 143: 1446–1449, 1986PubMedGoogle Scholar
  87. Saito H, Yagasaki A, Takahashi N, Hariguchi S, Takeda M, et al. Clinical efficacy of tiapride against some symptoms peculiar to the elderly. [Translated into English from Japanese.] Kiso Rinsho 19: 745–755, 1985Google Scholar
  88. Satlin A, Wolken L, Ross N, Herz L, Campbell S. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer’s disease. Abstract. Journal of the American Geriatrics Society 40: 1292, 1992Google Scholar
  89. Satoh H, Nakanishi H, Shirakawa K, Kohjimoto Y, Kuwaki T, et al. Comparative study of tiapride and neuroleptics with anti-dopamine activity on convulsive seizure in mice. Japanese Journal of Pharmacology 43: 27–32, 1987PubMedCrossRefGoogle Scholar
  90. Satoh H, Terai T, Nakanishi H, Ono T, Shibayama F. Effect of tiapride on the activity of neuroleptic and other kinds of drugs in mice and rats. Folia Pharmacologica Japonica 91: 71–80, 1988PubMedCrossRefGoogle Scholar
  91. Sauvage P, Pareaud M, Labrousse A, Meyer S, Bouthier F. Prise en charge des troubles du comportement du sujet âgé. ‘Intérêt du tiapride’. Psychologie Medicate 21: 1187–1196, 1989Google Scholar
  92. Scatton B, Bischoff S, Dedek J, Korf J. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. European Journal of Pharmacology 44: 287–292, 1977PubMedCrossRefGoogle Scholar
  93. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society 38: 553–563, 1990PubMedGoogle Scholar
  94. Shimizu M. The clinical effect of tiapride in patients with senile psychomotor disturbance. [Translated into English from Japanese.] Rinsho Seishin Igaku 11: 1497–1507, 1982Google Scholar
  95. Shimizu M, Hasegawa K, Nishimura T, Miyasaka M, Ishino H, et al. A multicentre, double-blind comparative study of tiapride and chlorpromazine in patients with psychiatric disorders of the aged. [Translated into English from Japanese.] Rinsho Seishin Igaku 27: 573–582, 1985Google Scholar
  96. Singer L. Traitement psychiatrique des personnes âgées. Psychothérapie et chimiothérapie. Journal de Médicine de Strasbourg 15: 181–183, 1984Google Scholar
  97. Sokoloff P, Martres MP, Schwartz JC. Three classes of dopamine receptors (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone. Naunyn-Schmiedeberg’s Archives of Pharmacology 315: 89–102, 1980PubMedCrossRefGoogle Scholar
  98. Stanley M, Wilk S. Striatal DOPAC elevation predicts antipsychotic efficacy of metoclopramide. Life Sciences 24: 1907–1912, 1979PubMedCrossRefGoogle Scholar
  99. Stefanini E, Clément-Cormier Y, Vernaleone F, Devoto P, Marchisio AM, et al. Sodium-dependent interaction of benzamides with dopamine receptors in rat and dog anterior pituitary glands. Neuroendocrinology 32: 103–107, 1981PubMedCrossRefGoogle Scholar
  100. Strolin-Benedetti M, Donath A, Frigerio A, Morgan KT, Laville C, et al. Absorption, élimination et métabolisme du tiapride (FLO 1347), médicament neuroleptique, chez le Rat, le Chien et l’Homme. Annates Pharmaceutiques Françaises 36: 279–288, 1978Google Scholar
  101. Strolin-Benedetti M, Donath A, Malnoe A. Étude pharmacocinétique et métabolique du tiapride chez homme. Semaine des Hôpitaux Paris 53(39B): 69–71, 1977Google Scholar
  102. Suzuki T, Kuwahara M, Shirokawa Y. Clinical experience of tiapride fine granule in elderly patients with psychiatric disorders. [Translated into English from Japanese.] Shinryo to Shinyaku 21: 213–222, 1984Google Scholar
  103. Taillefer S-M, Sauvage Ph. Un traitement original des troubles du sommeil, de l’anxieté et de l’agitation du sujet âgé: le tiapride. Semaine des Hôpitaux 59: 2049–2052, 1983PubMedGoogle Scholar
  104. Tamion F, Petit J, Massari P, Leroy J, Biga N, et al. Syndrome malin des neuroleptiques au cours d’un traitement par le tiapride. Journal de Toxicologic Clinique et Expérimentale 10: 461–467, 1990Google Scholar
  105. Vasse M, Protais P. Increased grooming behaviour is induced by apomorphine in mice treated with discriminant benzamide derivatives. European Journal of Pharmacology 156: 1–11, 1988PubMedCrossRefGoogle Scholar
  106. Vasse M, Protais P, Costentin J, Schwartz J-C. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn-Schmiedeberg’s Archives of Pharmacology 329: 108–116, 1985PubMedCrossRefGoogle Scholar
  107. von Aschoff JC, Claus D, Hetzel WD, Zur therapie zentralbedingter bewegungsanomalien mit tiaprid. Untersuchung des serumspiegels von prolactin, LH und FSH. Arzneimittel-Forschung 32: 286–289, 1982PubMedGoogle Scholar
  108. Wadworth AN, Heel RC. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40: 863–879, 1990PubMedCrossRefGoogle Scholar
  109. Wallach MB, Hedley LR, Peterson KE, Schulz CH. Antagonism of apomorphine induced climbing: is it a valid model for neuroleptic activity? Proceedings of the Western Pharmacology Society 23: 93–98, 1980PubMedGoogle Scholar
  110. Yamada M, Ikeda T, Maruo T, Usami K, Habu K, et al. Clinical usefulness of tiapride fine granule in the elderly patient with psychiatric disorders. In Japanese. Therapeutic Research 1: 817–827, 1984Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • John W. Steele
    • 1
  • Diana Faulds
    • 1
  • Eugene M. Sorkin
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations